JP2013538811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538811A5 JP2013538811A5 JP2013527261A JP2013527261A JP2013538811A5 JP 2013538811 A5 JP2013538811 A5 JP 2013538811A5 JP 2013527261 A JP2013527261 A JP 2013527261A JP 2013527261 A JP2013527261 A JP 2013527261A JP 2013538811 A5 JP2013538811 A5 JP 2013538811A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- difluoro
- fluoropyridin
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 65
- 125000005843 halogen group Chemical group 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000001188 haloalkyl group Chemical group 0.000 claims 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 23
- 125000003342 alkenyl group Chemical group 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- -1 deutero Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 102000042838 JAK family Human genes 0.000 claims 3
- 108091082332 JAK family Proteins 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- MCPUGZZCUANBFN-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 MCPUGZZCUANBFN-UHFFFAOYSA-N 0.000 claims 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- WJSZYWGOYIGLGU-UHFFFAOYSA-N (5-fluoropyridin-2-yl)-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]methanone Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(=O)C=2N=CC(F)=CC=2)=N1 WJSZYWGOYIGLGU-UHFFFAOYSA-N 0.000 claims 1
- XSAGVFXKVFDMTD-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-8-ol Chemical compound N1C(C)=CC(NC=2C3=CC=CC(O)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 XSAGVFXKVFDMTD-UHFFFAOYSA-N 0.000 claims 1
- AKQURCCBNQDETN-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazoline-7-carbonitrile Chemical compound N1C(C)=CC(NC=2C3=CC=C(C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C#N)=N1 AKQURCCBNQDETN-UHFFFAOYSA-N 0.000 claims 1
- NTKQWKUTRQTFHU-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazoline-7-carboxamide Chemical compound N1C(C)=CC(NC=2C3=CC=C(C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C(N)=O)=N1 NTKQWKUTRQTFHU-UHFFFAOYSA-N 0.000 claims 1
- GRAFFBOCVCOJFB-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazoline-8-carbonitrile Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C#N)=N1 GRAFFBOCVCOJFB-UHFFFAOYSA-N 0.000 claims 1
- AFBDKDHZBJKSKU-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazoline-8-carboxamide Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C(N)=O)=N1 AFBDKDHZBJKSKU-UHFFFAOYSA-N 0.000 claims 1
- AZYCUZXYDSPFPA-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazoline-8-carboxylic acid Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C(O)=O)=N1 AZYCUZXYDSPFPA-UHFFFAOYSA-N 0.000 claims 1
- OYMYXSBBFUQPIL-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-4,8-diamine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(N)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 OYMYXSBBFUQPIL-UHFFFAOYSA-N 0.000 claims 1
- RCFRWCSGGDOFJU-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-7-fluoro-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=C(F)C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 RCFRWCSGGDOFJU-UHFFFAOYSA-N 0.000 claims 1
- GKEWJWUPVPYMLI-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-7-methoxy-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N=1C(C(F)(F)C=2N=CC(F)=CC=2)=NC2=CC(OC)=CC=C2C=1NC=1C=C(C)NN=1 GKEWJWUPVPYMLI-UHFFFAOYSA-N 0.000 claims 1
- OXJGKGUEVPDQCU-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-7-methyl-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=C(C)C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 OXJGKGUEVPDQCU-UHFFFAOYSA-N 0.000 claims 1
- GRGVDWYUVCSJMX-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-8-ethyl-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1=C(C(F)(F)C=2N=CC(F)=CC=2)N=C2C(CC)=CC=CC2=C1NC=1C=C(C)NN=1 GRGVDWYUVCSJMX-UHFFFAOYSA-N 0.000 claims 1
- WQLBBCBDQAJOOC-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-8-fluoro-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(C(F)(F)C=2N=CC(F)=CC=2)=NC2=C(F)C=CC=C12 WQLBBCBDQAJOOC-UHFFFAOYSA-N 0.000 claims 1
- IZHLPEWWMLJSNT-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-8-methoxy-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1=C(C(F)(F)C=2N=CC(F)=CC=2)N=C2C(OC)=CC=CC2=C1NC=1C=C(C)NN=1 IZHLPEWWMLJSNT-UHFFFAOYSA-N 0.000 claims 1
- VUVSRGDNNDBVMC-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-8-methyl-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(C)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 VUVSRGDNNDBVMC-UHFFFAOYSA-N 0.000 claims 1
- OFSKVQPOFGIYDU-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(1h-1,2,4-triazol-5-yl)quinazolin-4-amine Chemical compound N1=CC(F)=CC=C1C(F)(F)C1=NC(NC2=NNC=N2)=C(C=CC=C2)C2=N1 OFSKVQPOFGIYDU-UHFFFAOYSA-N 0.000 claims 1
- VENZULZJTMPHNG-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(1h-pyrazol-5-yl)quinazolin-4-amine Chemical compound N1=CC(F)=CC=C1C(F)(F)C1=NC(NC2=NNC=C2)=C(C=CC=C2)C2=N1 VENZULZJTMPHNG-UHFFFAOYSA-N 0.000 claims 1
- LHLIXVZUNHDMSG-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(3-methoxy-1h-pyrazol-5-yl)quinazolin-4-amine Chemical compound N1C(OC)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 LHLIXVZUNHDMSG-UHFFFAOYSA-N 0.000 claims 1
- HCSAVAZCQDKKPA-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-7-methylsulfonylquinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=C(C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)S(C)(=O)=O)=N1 HCSAVAZCQDKKPA-UHFFFAOYSA-N 0.000 claims 1
- DIGAICBRKCJUKN-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-8-(trifluoromethoxy)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(OC(F)(F)F)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 DIGAICBRKCJUKN-UHFFFAOYSA-N 0.000 claims 1
- XGQRMNKMJMRGFH-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-8-(trifluoromethyl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C(F)(F)F)=N1 XGQRMNKMJMRGFH-UHFFFAOYSA-N 0.000 claims 1
- UZAWFVAJUIRMHB-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-8-methylsulfonylquinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)S(C)(=O)=O)=N1 UZAWFVAJUIRMHB-UHFFFAOYSA-N 0.000 claims 1
- QIQBBKOUAZIQLI-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-8-nitroquinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)[N+]([O-])=O)=N1 QIQBBKOUAZIQLI-UHFFFAOYSA-N 0.000 claims 1
- OUKOVJNIVQXTTO-UHFFFAOYSA-N 2-[difluoro-(5-fluoropyrimidin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CN=2)=N1 OUKOVJNIVQXTTO-UHFFFAOYSA-N 0.000 claims 1
- ITGPPFYDRDMILH-UHFFFAOYSA-N 4-[2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-8-yl]morpholin-3-one Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)N2C(COCC2)=O)=N1 ITGPPFYDRDMILH-UHFFFAOYSA-N 0.000 claims 1
- VEZOFKZEICNRLT-UHFFFAOYSA-N 7-bromo-2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=C(Br)C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 VEZOFKZEICNRLT-UHFFFAOYSA-N 0.000 claims 1
- VCGNNBOHYVSYGP-UHFFFAOYSA-N 7-chloro-2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=C(Cl)C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 VCGNNBOHYVSYGP-UHFFFAOYSA-N 0.000 claims 1
- KPLWMQFXJQFKCV-UHFFFAOYSA-N 7-cyclopropyl-2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=C(C=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C2CC2)=N1 KPLWMQFXJQFKCV-UHFFFAOYSA-N 0.000 claims 1
- OTIYGQSDZBIJOQ-UHFFFAOYSA-N 8-bromo-2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(Br)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 OTIYGQSDZBIJOQ-UHFFFAOYSA-N 0.000 claims 1
- RXZIVJQQEIEMRY-UHFFFAOYSA-N 8-chloro-2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(Cl)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 RXZIVJQQEIEMRY-UHFFFAOYSA-N 0.000 claims 1
- AVYNZYUHAHIQFN-UHFFFAOYSA-N 8-chloro-2-[difluoro-(5-fluoropyrimidin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(Cl)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CN=2)=N1 AVYNZYUHAHIQFN-UHFFFAOYSA-N 0.000 claims 1
- GEADPOFVBCFLNQ-UHFFFAOYSA-N 8-cyclopropyl-2-[difluoro-(5-fluoropyridin-2-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)C2CC2)=N1 GEADPOFVBCFLNQ-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003943 azolyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000005345 deuteroalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- RVRNEQGLBYKMIT-UHFFFAOYSA-N methyl 2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazoline-8-carboxylate Chemical compound N1=C(C(F)(F)C=2N=CC(F)=CC=2)N=C2C(C(=O)OC)=CC=CC2=C1NC=1C=C(C)NN=1 RVRNEQGLBYKMIT-UHFFFAOYSA-N 0.000 claims 1
- QKGQVICNBSLZRB-UHFFFAOYSA-N n-[2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-8-yl]acetamide Chemical compound N1=C(C(F)(F)C=2N=CC(F)=CC=2)N=C2C(NC(=O)C)=CC=CC2=C1NC=1C=C(C)NN=1 QKGQVICNBSLZRB-UHFFFAOYSA-N 0.000 claims 1
- WUCMBDFBFRKMIA-UHFFFAOYSA-N n-[2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-8-yl]formamide Chemical compound N1C(C)=CC(NC=2C3=CC=CC(NC=O)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 WUCMBDFBFRKMIA-UHFFFAOYSA-N 0.000 claims 1
- PDHQHMTWSXHWJT-UHFFFAOYSA-N n-[2-[difluoro-(5-fluoropyridin-2-yl)methyl]-4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-8-yl]methanesulfonamide Chemical compound N1C(C)=CC(NC=2C3=CC=CC(NS(C)(=O)=O)=C3N=C(N=2)C(F)(F)C=2N=CC(F)=CC=2)=N1 PDHQHMTWSXHWJT-UHFFFAOYSA-N 0.000 claims 1
- AOXNIUAQZPKOSC-UHFFFAOYSA-N n-[2-[difluoro-(5-fluoropyridin-2-yl)methyl]quinazolin-4-yl]-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(C)=CN=C1NC1=NC(C(F)(F)C=2N=CC(F)=CC=2)=NC2=CC=CC=C12 AOXNIUAQZPKOSC-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 CN(C1N(*)c2n[n](*)c(*)c2)C(C(*)(*)C(*)=*IC=CC=C)=Nc2c1cccc2 Chemical compound CN(C1N(*)c2n[n](*)c(*)c2)C(C(*)(*)C(*)=*IC=CC=C)=Nc2c1cccc2 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37930910P | 2010-09-01 | 2010-09-01 | |
| US61/379,309 | 2010-09-01 | ||
| PCT/US2011/049950 WO2012030948A1 (en) | 2010-09-01 | 2011-08-31 | Quinazoline compounds and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538811A JP2013538811A (ja) | 2013-10-17 |
| JP2013538811A5 true JP2013538811A5 (enExample) | 2014-10-09 |
| JP5901634B2 JP5901634B2 (ja) | 2016-04-13 |
Family
ID=44645826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527261A Expired - Fee Related JP5901634B2 (ja) | 2010-09-01 | 2011-08-31 | キナゾリン化合物及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8633207B2 (enExample) |
| EP (1) | EP2611789A1 (enExample) |
| JP (1) | JP5901634B2 (enExample) |
| KR (1) | KR20130102060A (enExample) |
| CN (1) | CN103298805A (enExample) |
| AU (1) | AU2011296024B2 (enExample) |
| CA (1) | CA2810024A1 (enExample) |
| MX (1) | MX2013002384A (enExample) |
| WO (1) | WO2012030948A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013135674A1 (en) * | 2012-03-12 | 2013-09-19 | Syngenta Participations Ag | Insecticidal 2-aryl-acetamide compounds |
| CN103301133B (zh) * | 2012-12-11 | 2014-09-17 | 中国药科大学 | 一类氨基喹唑啉表皮生长因子受体拮抗剂的抗肿瘤治疗用途 |
| WO2016049532A1 (en) | 2014-09-26 | 2016-03-31 | Unitract Syringe Pty Ltd | Sequential chamber drug delivery pumps for drug mixing and delivery |
| JP2018135268A (ja) * | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩 |
| CN105503837B (zh) * | 2015-12-31 | 2018-06-29 | 中山大学 | 具有Aurora激酶抑制活性的取代喹唑啉类衍生物及其应用 |
| EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| CN107375308B (zh) * | 2017-09-04 | 2021-02-12 | 四川美大康药业股份有限公司 | 毛蕊花糖苷在制备预防或治疗肾小球足细胞损伤型肾脏疾病的药物中的用途 |
| CN116323623B (zh) | 2020-09-18 | 2025-09-26 | 拜耳公司 | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN116283994B (zh) * | 2021-12-20 | 2025-01-07 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的杂环化合物 |
| WO2024056782A1 (en) | 2022-09-16 | 2024-03-21 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
| CN120112538A (zh) | 2022-10-13 | 2025-06-06 | 拜耳公司 | Sos1抑制剂 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| CA2219698C (en) | 1996-10-31 | 2007-09-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| WO1998022460A1 (en) | 1996-11-15 | 1998-05-28 | Darwin Discovery Limited | Bicyclic aryl carboxamides and their therapeutic use |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| KR20000057693A (ko) | 1996-12-20 | 2000-09-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 지효성 제제의 제조 방법 |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| NZ505651A (en) | 1998-01-16 | 2003-08-29 | Takeda Chemical Industries Ltd | Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AU2001276608A1 (en) | 2000-08-30 | 2002-03-13 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE354573T1 (de) | 2000-12-21 | 2007-03-15 | Vertex Pharma | ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß |
| CA2473796A1 (en) | 2002-01-17 | 2003-07-31 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues |
| EP1485380B1 (en) * | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
| EP1485381B8 (en) * | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
| US7091343B2 (en) * | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7112435B1 (en) | 2002-08-07 | 2006-09-26 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| GB0220187D0 (en) | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| JP4695395B2 (ja) | 2002-12-13 | 2011-06-08 | ニューロジェン・コーポレーション | 疼痛治療用の併用療法 |
| CA2509239A1 (en) | 2002-12-13 | 2004-07-01 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター：使用および合成の方法 |
| JP2007509985A (ja) | 2003-10-31 | 2007-04-19 | ニューロジェン・コーポレーション | カプサイシン受容体作動薬 |
| CA2588220A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| US9110054B2 (en) | 2006-06-30 | 2015-08-18 | Discoverx Corporation | Detectable nucleic acid tag |
| MX2009010127A (es) | 2007-03-22 | 2009-11-05 | Vertex Pharma | Compuestos utiles como inhibidores de janus cinasas. |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| DK2740731T3 (en) | 2007-06-13 | 2016-04-11 | Incyte Holdings Corp | CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL |
| RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
| CN101463014B (zh) | 2008-12-26 | 2013-07-10 | 复旦大学 | 二芳基苯并嘧啶类衍生物及其药物组合物和用途 |
| CN102395576A (zh) * | 2009-02-27 | 2012-03-28 | 埃姆比特生物科学公司 | 调控jak激酶的喹唑啉衍生物和其使用方法 |
| WO2011088045A1 (en) | 2010-01-12 | 2011-07-21 | Ambit Biosciences Corporation | Aurora kinase compounds and methods of their use |
| US20120053176A1 (en) | 2010-09-01 | 2012-03-01 | Ambit Biosciences Corp. | Adenosine a3 receptor modulating compounds and methods of use thereof |
-
2011
- 2011-08-31 CA CA2810024A patent/CA2810024A1/en not_active Abandoned
- 2011-08-31 EP EP11755510.2A patent/EP2611789A1/en not_active Withdrawn
- 2011-08-31 US US13/222,937 patent/US8633207B2/en not_active Expired - Fee Related
- 2011-08-31 WO PCT/US2011/049950 patent/WO2012030948A1/en not_active Ceased
- 2011-08-31 KR KR1020137007907A patent/KR20130102060A/ko not_active Ceased
- 2011-08-31 JP JP2013527261A patent/JP5901634B2/ja not_active Expired - Fee Related
- 2011-08-31 AU AU2011296024A patent/AU2011296024B2/en not_active Ceased
- 2011-08-31 MX MX2013002384A patent/MX2013002384A/es not_active Application Discontinuation
- 2011-08-31 CN CN2011800527654A patent/CN103298805A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538811A5 (enExample) | ||
| US10519158B2 (en) | Inhibiting the transient receptor potential A1 ion channel | |
| RU2016129953A (ru) | Фармацевтические комбинации | |
| RU2011139321A (ru) | Модулирующие jak киназу хиназолиновые производные и способы их применения | |
| JP2012519179A5 (enExample) | ||
| JP2016512558A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| RU2013155456A (ru) | Соединения пирролидинилмочевины и пирролидинилтиомочевины как ингибиторы киназы trka | |
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| JP2016528301A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2012515787A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2012532131A5 (enExample) | ||
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| JP2009542815A5 (enExample) | ||
| HRP20130120T1 (hr) | Analozi piridona i piridazona kao gpr119 modulatori | |
| JP2016539138A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| JP2012522748A5 (enExample) | ||
| IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
| JP2016512507A5 (enExample) | ||
| JP2009532438A5 (enExample) | ||
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич |